The Government has published the level of payment due from members of the Pharmaceutical Price Regulation Scheme (PPRS) in 2017 to keep health service spend on branded medicines within the levels agreed under the Scheme.
The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), have responded to the Prime Minister's speech on the Government's negotiating objectives for exiting the EU.
The new Health Service Medical Supplies Bill has completed its path through Parliament and is now law. David Watson, ABPI Director of Pricing & PPRS, analyses the key aspects of the new legislation, the areas where ABPI had concerns, the immediate relevance to industry and where we will continue...
Last week ABPI members heard the latest research into the behaviours of patients in taking their medicines and were presented with opportunities around industry’s role in patient adherence.
Following the announcement of the Government’s Early Access to Medicines Scheme, the ABPI and the BIA jointly invite you to attend our event to understand and discuss this important policy announcement giving you an early opportunity to hear first-hand from senior policymakers involved in the Scheme...
My Lords, Ladies and Gentlemen it is a pleasure to welcome you all here this evening.
Thank you for your introduction Stephen. I am delighted that you have given me this opportunity to speak again, at this important occasion.
In advance of the ABPI's Annual Conference 2017 'Seizing the opportunity for Life Sciences in the UK' on 27 April , Steve Bates, OBE, Chief Executive of the BioIndustry Association, highlights how the UK is a leading global cluster for Life Sciences.
This extended analysis was authored by Colette Goldrick, ABPI Director of NHS Engagement, in response to today's (5 April) House of Lords Long-Term Sustainability of the NHS Committee report.
The Department of Health has today [27 October] published the Q2 2017 PPRS data showing that the pharmaceutical industry has paid a total of £190 million during the first two quarters of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).